Constellation Brands Announces Departure of E. Yuri Hermida, Executive Vice President, Chief Growth & Strategy Officer
Mallika Monteiro to serve as interim Chief Growth & Strategy Officer, in addition to her current responsibilities as Executive Vice President, Managing Director – Beer Brands
ROCHESTER, N.Y., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Constellation Brands (NYSE: STZ), a leading beverage alcohol company, today announced that E. Yuri Hermida, Executive Vice President, Chief Growth & Strategy Officer, will depart the company effective February 28, 2025 to pursue career interests outside the organization. Mallika Monteiro, Executive Vice President, Managing Director – Beer Brands, will serve as interim Chief Growth & Strategy Officer, in addition to her current responsibilities, to assist in managing through this transition.
'Yuri made a difficult decision to leave Constellation Brands to pursue a life-long career goal and we wish him the very best in his future endeavors,' said Bill Newlands, President and Chief Executive Officer at Constellation Brands. 'Mallika will serve as interim Chief Growth & Strategy Officer, in addition to her current responsibilities leading our Beer Marketing organization, as we work through this transition. She is well-versed in the important work being done across all facets of our Growth team, having served as Constellation's former Chief Growth & Strategy Officer. I look forward to our Growth team's continued contributions as we progress towards our company's long-term aspirations.'
ABOUT CONSTELLATION BRANDSConstellation Brands (NYSE: STZ) is a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Our mission is to build brands that people love because we believe elevating human connections is Worth Reaching For. It's worth our dedication, hard work, and calculated risks to anticipate market trends and deliver more for our consumers, shareholders, employees, and industry. This dedication is what has driven us to become one of the fastest-growing, large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what's next.
Every day, people reach for our high-end, iconic imported beer brands such as those in the Corona brand family like the flagship Corona Extra, Modelo Especial and the flavorful lineup of Modelo Cheladas, Pacifico, and Victoria; our fine wine and craft spirits brands including The Prisoner Wine Company, Robert Mondavi Winery, Casa Noble Tequila, and High West Whiskey; and our premium wine brands such as Kim Crawford and Meiomi.
As an agriculture-based company, we have a long history of operating sustainably and responsibly. Our ESG strategy is embedded into our business and our work focuses on serving as good stewards of the environment, enhancing social equity within our industry and communities, and promoting responsible beverage alcohol consumption. These commitments ground our aspirations beyond driving the bottom line as we work to create a future that is truly Worth Reaching For.
To learn more, visit www.cbrands.com and follow us on X, Instagram, and LinkedIn.
FORWARD-LOOKING STATEMENTSThis news release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements. The word 'expect' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements may relate to business strategy, future operations, prospects, plans, and objectives of management, including the contributions of Constellation's Growth team and the Company's progression towards its long-term aspirations, as well as information concerning expected actions of third parties. All forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those set forth in, or implied by, such forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur.
The forward-looking statements are based on management's current expectations and should not be construed in any manner as a guarantee that such results will in fact occur. All forward-looking statements speak only as of the date of this news release and Constellation does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
In addition to risks and uncertainties associated with ordinary business operations, the forward-looking statements contained in this news release are subject to other risks and uncertainties, including the accuracy of all projections and other factors and uncertainties disclosed from time-to-time in Constellation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended February 29, 2024 and its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2024, which could cause actual future performance to differ from current expectations.
MEDIA CONTACTS
INVESTOR RELATIONS CONTACTS
Amy Martin 585-678-7141 / amy.martin@cbrands.comCarissa Guzski 315-525-7362 / carissa.guzski@cbrands.com
Joseph Suarez 773-551-4397 / joseph.suarez@cbrands.comSnehal Shah 847-385-4940 / snehal.shah@cbrands.comDavid Paccapaniccia 585-282-7227 / david.paccapaniccia@cbrands.com
A downloadable PDF copy of this news release can be found here http://ml.globenewswire.com/Resource/Download/c2df6c8c-a711-4dab-85b6-ee7d9e196821Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
$13.16 Bn Human Growth Hormone (HGH) Market Trends and Forecasts, 2020-2024 & 2025-2030: Strategic R&D Initiatives, Regulatory Approvals, and Collaborations Shaping the Landscape
The Human Growth Hormone market offers significant opportunities driven by the rise in growth hormone deficiencies and aging populations seeking HGH therapy. The demand is boosted by potential anti-aging and wellness benefits, with biosimilars presenting a cost-effective alternative. Key challenges include high costs and ethical issues. Human Growth Hormone (HGH) Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Human Growth Hormone (HGH) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Human Growth Hormone (HGH) Market was valued at USD 6.21 Billion in 2024, and is expected to reach USD 13.16 Billion by 2030, rising at a CAGR of 13.29% This rapidly evolving sector within the pharmaceutical and biotechnology industry centers on the use of somatotropin - a crucial hormone produced by the pituitary gland - to support growth, development, and metabolic functions. Key growth drivers include the rising prevalence of growth hormone deficiencies (GHD), especially among children, and increased interest in HGH therapy among the aging population to address age-related hormonal decline. In addition to its approved medical applications, HGH is being explored for its potential anti-aging and wellness benefits, further expanding its demand. The market features a wide range of products, including recombinant human growth hormone (rhGH) and biosimilars, with injectable formulations dominating the segment. Strategic R&D initiatives, regulatory approvals, and collaborations among pharmaceutical companies are shaping the market's competitive landscape. However, accessibility issues and high treatment costs remain challenges, alongside ethical concerns about off-label use for enhancement Market Drivers Increasing Prevalence of Growth Hormone Deficiency (GHD)The growing incidence of Growth Hormone Deficiency (GHD) remains a primary catalyst for the Human Growth Hormone (HGH) market globally. GHD, caused by inadequate hormone secretion from the pituitary gland, significantly affects growth, especially in children, and impacts overall health in adults. Current estimates suggest that GHD occurs in 1 out of every 4,000 to 10,000 live births, with a substantial number of adult-onset cases recorded annually. Greater awareness and improved diagnostic tools have enabled earlier detection and intervention, enhancing patient factors include poor nutrition, increased stress, genetic disorders, and medical conditions involving the hypothalamic-pituitary axis. As access to healthcare broadens, more individuals are seeking evaluation and treatment for growth-related disorders, spurring pharmaceutical companies to develop long-acting therapies and improve patient compliance. This growing patient population continues to drive demand for HGH treatment solutions Market Challenges High CostCost remains a significant barrier in the Global Human Growth Hormone (HGH) Market. The complex production process of recombinant human growth hormone (rhGH), involving high-end biotechnological methods and rigorous quality standards, contributes to elevated prices. The long duration of therapy, often lasting several years, further increases the financial burden on patients and healthcare systems. Limited insurance coverage in certain regions and insufficient public health resources exacerbate access issues. As a result, many patients are unable to afford or maintain treatment, especially in lower-income markets. Addressing affordability through cost-effective production and pricing strategies is essential to broaden access to life-enhancing HGH Market Trends BiosimilarsThe growing presence of biosimilars is a transformative trend in the Global Human Growth Hormone (HGH) Market. These are biologic products designed to closely resemble original rhGH therapies in terms of safety, efficacy, and quality, but at a more accessible price point. Biosimilars undergo stringent regulatory scrutiny and clinical testing to ensure comparable performance to reference introduction promotes market competition, helping to reduce treatment costs and improve patient access. As biosimilar adoption expands, particularly in cost-sensitive regions, their role in the market is increasing. Nevertheless, regulatory approval processes, interchangeability protocols, and manufacturing consistency remain key considerations. Overall, biosimilars represent a promising path toward greater affordability and availability of HGH treatments. Key Attributes: Report Attribute Details No. of Pages 185 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $6.21 Billion Forecasted Market Value (USD) by 2030 $13.16 Billion Compound Annual Growth Rate 13.2% Regions Covered Global Report Scope: Key Market Players Novo Nordisk A/S Eli Lilly and Company Pfizer, Inc. Sandoz International GmbH (Novartis AG) Genentech, Inc. (Roche) Merck KGaA Ferring Pharmaceuticals Ipsen Pharma Teva Pharmaceutical Industries, Ltd. Human Growth Hormone (HGH) Market, By Product: Long Acting Others Human Growth Hormone (HGH) Market, By Application: Growth Hormone (GH) Deficiency Turner Syndrome Idiopathic Short Stature Prader-Willi Syndrome Small for Gestational Age Other Human Growth Hormone (HGH) Market, By Distribution Channel: Hospital Pharmacy Retail Pharmacy Online Pharmacy Specialty Pharmacy Human Growth Hormone (HGH) Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Growth Hormone (HGH) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
ATKORE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Atkore Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ('KSF'), announces that KSF has commenced an investigation into Atkore Inc. (NYSE: ATKR). In July 2024, the Company was named as a defendant in a number of civil antitrust lawsuits alleging that, from at least April 1, 2021, it and other U.S.-based PVC Pipe manufacturers conspired to artificially inflate the price of PVC Pipes through the exchange of competitively sensitive business information regarding PVC Pipe pricing and sales through an industry newsletter called Oil Price Information Service, LLC ('OPIS'), in violation of federal antitrust laws. Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information in violation of federal securities laws, which remains ongoing. KSF's investigation is focusing on whether Atkore's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. If you have information that would assist KSF in its investigation, or have been a long-term holder of Atkore shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ( or visit to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. To learn more about KSF, you may visit
Yahoo
2 hours ago
- Yahoo
Circle Goes Full Circle
By sheer luck, I had an opening bell media hit with NYSE TV this last Thursday, the day Circle listed as CRCL. The NYSE studio is upstairs at gallery level. I'd first visited the NYSE on the same gallery balcony as a boy with my Dad. I remember getting the impression that IBM was a huge company that represented the future. Circle staff and guests filed in at 9:15, a much larger delegation than most bell-ringings. Not only was the floor packed, but both galleries were full. As the applause started, precisely at 9:29:30, everything else stopped. This wasn't the usual opening bell tea ceremony. NYSE President Lynn Martin stood beside an air-punching Circle CEO Jeremy Allaire, and the specialists, floor brokers, and other floor inhabitants joined in the cacophony. The energy took over the whole floor in a way that felt exceptional. I asked, cheekily, to the NYSE TV folks which specialist booth would trade CRCL. No one had any idea what I was talking about. The producer decided to move our hit to the floor with a handheld microphone and change our subject from bitcoin to stablecoins on the fly. That was fine—plenty to say about stablecoins. Standing within feet of Jeremy Allaire on the floor next to the bell balcony, doing our five-minute segment, it was pure electricity. It was the feeling when you finish a marathon and a beaming volunteer places a medal around your neck. Accomplishment and validation. This was a moment enabled by a friendlier SEC and coincident with meaningful blockchain legislation, but it didn't have the vibe of MSTR rapture or youthful DeFi exuberance. It felt mature and financial--adults celebrating. USDC sprang to life in September 2018, just before a local peak in U.S. interest rates. In retrospect, it was a handy time to launch, when carry (yield from backing assets) was positive but yield expectations in crypto (whose practitioners mostly grew up in a zero interest rate world) remained low. When COVID hit, in 2020, ZIRP (Zero-Interest-Rate-Policy) returned suddenly, threatening the business model, but prompting crypto adoption and experimentalism. When the Fed aggressively raised rates in 2022 to help metabolize $5 trillion in COVID fiscal stimulus, stablecoins faced the opposite combination of supportive and threatening forces: higher carry revenues, but traumatized markets. Circle's failed SPAC attempt spanned this transition. Announced in July 2021 when 3-month yields were 0.05%, the Concord Acquisition deal was renegotiated in February 2022 (as rates began their historic climb) and ultimately terminated in December 2022—right as rates hit 4.42%. The SEC never declared the S-4 registration statement effective. The transaction "timed out" waiting for regulatory approval, just as the underlying economics of Circle's business were being boosted by soaring rates. Now, several years into a 4-5% rate environment, the model has adapted and appears to be working. USDC holders can receive "rewards" on Coinbase that are similar to risk-free yields. On-chain cash holdings and collateral can be enhanced with tokenized treasuries. The GENIUS Act on stablecoins appears in good shape for passage, opening up the market for greater stablecoin adoption and participation. The U.S. government has a new potential multi-trillion dollar customer for U.S. treasuries, providing much-needed demand for U.S. debt, which has become a chess piece in global trade. Circle (and other stablecoin issuers) are enjoying a good carry scenario, although near-term profitability has significant interest rate risk, now under the watchful scrutiny of CRCL shareholders and analysts. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
